Get the Stockscreener App
45.31
1.20%
-0.47
Ultragenyx Pharmaceutical Inc stock is traded at $45.31, with a volume of 337.62K.
It is down -1.20% in the last 24 hours and up +1.78% over the past month.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
See More
Previous Close:
$45.78
Open:
$45.73
24h Volume:
337.62K
Relative Volume:
0.40
Market Cap:
$4.22B
Revenue:
$522.75M
Net Income/Loss:
$-558.99M
P/E Ratio:
-7.0031
EPS:
-6.47
Net Cash Flow:
$-439.53M
1W Performance:
+5.11%
1M Performance:
+1.78%
6M Performance:
-7.58%
1Y Performance:
+1.16%
1-Day Range:
$45.02
$46.15
1-Week Range:
$41.89
$46.50
52-Week Range:
$37.02
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Name
Ultragenyx Pharmaceutical Inc
Sector
Industry
Phone
415-483-8800
Address
60 LEVERONI COURT, NOVATO, CA
Compare RARE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
45.26 | 4.22B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.76 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.62 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.19 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.15 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.44 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-06-24 | Upgrade | Goldman | Neutral → Buy |
| Apr-22-24 | Initiated | RBC Capital Mkts | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Jun-06-23 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-18-23 | Resumed | Canaccord Genuity | Buy |
| Dec-30-22 | Resumed | H.C. Wainwright | Buy |
| Nov-03-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-13-22 | Upgrade | Guggenheim | Neutral → Buy |
| Aug-01-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Mar-16-22 | Upgrade | Credit Suisse | Neutral → Outperform |
| Feb-11-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-30-21 | Initiated | H.C. Wainwright | Buy |
| Aug-19-21 | Initiated | UBS | Sell |
| Jul-15-21 | Initiated | Guggenheim | Neutral |
| Jun-29-21 | Upgrade | BofA Securities | Neutral → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| May-06-21 | Upgrade | Citigroup | Neutral → Buy |
| May-06-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Neutral |
| Mar-02-21 | Resumed | Stifel | Buy |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-07-20 | Downgrade | Wedbush | Outperform → Neutral |
| Nov-24-20 | Resumed | Evercore ISI | In-line |
| Nov-12-20 | Downgrade | BofA Securities | Buy → Neutral |
| Aug-02-19 | Resumed | Wedbush | Outperform |
| Mar-27-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Feb-22-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Nov-08-18 | Upgrade | Citigroup | Sell → Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-21-18 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-18 | Upgrade | Barclays | Equal Weight → Overweight |
| May-10-18 | Initiated | Goldman | Neutral |
| Apr-18-18 | Upgrade | SunTrust | Hold → Buy |
| Mar-22-18 | Resumed | Piper Jaffray | Overweight |
| Feb-21-18 | Reiterated | Stifel | Buy |
| Jan-22-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Jan-18-18 | Initiated | Credit Suisse | Outperform |
| Dec-05-17 | Reiterated | Barclays | Equal Weight |
| Dec-04-17 | Upgrade | Jefferies | Hold → Buy |
| Sep-14-17 | Upgrade | Wedbush | Neutral → Outperform |
View All
Ultragenyx Pharmaceutical Inc Stock (RARE) Latest News
Ultragenyx Pharmaceuticals: Buy Rating Supported by Promising Gene Therapy Trial Results and Regulatory Advancements - TipRanks
Brokerages Set Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) PT at $92.43 - MarketBeat
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2024 Financial Results and Corporate Update - GlobeNewswire
Rare Disease Leader Ultragenyx to Reveal Full Year Performance: Key Earnings Date Announced - StockTitan
Cognitive, motor skill gains seen with Sanfilippo syndrome type A gene therapy - Sanfilippo News
Rett Syndrome Market Growth Projections 2024-2034: - openPR
Adicet's T-Cell Therapy ADI-100 Fast Tracked by FDA for Refractory Systemic Lupus Erythematosus - CGTLive™
RARE Reports New Upbeat Data From Sanfilippo Syndrome Drug Study - Nasdaq
Ultragenyx announces new data on UX111 AV gene therapy - Yahoo Finance
Ultragenyx updates on UX111 AAV gene therapy - The Pharma Letter
Ultragenyx links cognitive improvement to biomarker in latest Sanfilippo gene therapy readout - FirstWord Pharma
Ultragenyx Pharmaceutical Presents New Data for UX111 Gene Therapy, Expects FDA Approval Decision in H2 - Marketscreener.com
Ultragenyx reports positive data on gene therapy for rare disease - MSN
Ultragenyx reports positive data on gene therapy for rare disease By Investing.com - Investing.com South Africa
Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustaine - GlobeNewswire
Breakthrough: Ultragenyx's Gene Therapy Reverses Cognitive Decline in Fatal Childhood Disease - StockTitan
KBC Group NV Buys 58,442 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Mucopolysaccharidosis Type III Pipeline 2024: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Takeda Pharma, BioMarin Pharma, Ultragenyx Pharma, Sarepta - Barchart
Ultragenyx Pharmaceutical: Advancing On Multiple Fronts (NASDAQ:RARE) - Seeking Alpha
Wilson’s Disease Market Expected to rise, 2034 | Orphalan, AstraZeneca,Vivet Therapeutics,Pfizer,Ultragenyx Pharmaceutical, expected to drive market - Barchart
Learn to Evaluate (RARE) using the Charts - Stock Traders Daily
Ultragenyx Pharmaceutical (NASDAQ:RARE) adds US$374m to market cap in the past 7 days, though investors from three years ago are still down 37% - Simply Wall St
What is Wedbush’s Estimate for RARE FY2024 Earnings? - Defense World
Wedbush Has Positive Outlook for RARE FY2027 Earnings - Defense World
Wedbush Equities Analysts Boost Earnings Estimates for RARE - MarketBeat
Ultragenyx's SWOT analysis: rare disease stock poised for growth - Investing.com India
Cantor Fitzgerald Forecasts RARE FY2025 Earnings - Defense World
FY2024 Earnings Estimate for RARE Issued By Leerink Partnrs - Defense World
Mucopolysaccharidosis (MPS) Treatment Market Growth in Future - openPR
Ultragenyx's SWOT analysis: rare disease stock poised for growth By Investing.com - Investing.com Australia
Breaking Down Ultragenyx Pharmaceutical: 11 Analysts Share Their Views - Benzinga
Ultragenyx Pharmaceutical's (RARE) "Overweight" Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Leerink Partnrs Has Positive Outlook of RARE FY2024 Earnings - MarketBeat
Cantor Fitzgerald Predicts RARE FY2025 Earnings - MarketBeat
Assenagon Asset Management S.A. Sells 76,160 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World
Assenagon Asset Management S.A. Decreases Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - MarketBeat
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
FY2024 EPS Estimates for RARE Boosted by Cantor Fitzgerald - Defense World
Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Down 5.7%Should You Sell? - MarketBeat
Why Ultragenyx Pharmaceutical (RARE) Is the Biotech Stock with the Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
FY2024 EPS Estimates for RARE Increased by Cantor Fitzgerald - MarketBeat
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Position Trimmed by Hennion & Walsh Asset Management Inc. - MarketBeat
J.P. Morgan Notebook: Priorities For The Year Ahead - News & Insights
Wealth Enhancement Advisory Services LLC Acquires 294 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) - Defense World
Ultragenyx's Multiple Commercial Assets And Candidates Impress Analyst; Sees Solid Upside - AOL
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 9.1%Here's Why - MarketBeat
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Raised to $140.00 at Piper Sandler - Defense World
Ultragenyx Pharmaceutical’s (RARE) “Neutral” Rating Reaffirmed at Wedbush - Defense World
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use - MSN
Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Expected to Rise, Piper Sandler Analyst Says - MarketBeat
Ultragenyx Pharmaceutical Inc Stock (RARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):